CAR-NK细胞的构建策略及其在肿瘤免疫治疗中的研究进展  

Construction strategy of CAR-NK cells and its research progress in tumor immunotherapy

作　　者：胡佳琪 高洁 HU Jia-qi;GAO Jie(Rheumatology and Immunology Department,the First Affiliated Hospital of Naval Medical University,SHANGHAI 200433,China)

机构地区：[1]海军军医大学第一附属医院风湿免疫科,上海200433

出　　处：《中国新药与临床杂志》2024年第11期801-808,共8页Chinese Journal of New Drugs and Clinical Remedies

基　　金：上海市卫生健康委员会临床科研项目(202340061);海军军医大学第一附属医院基础研究面上培育项目(2023PY40)。

摘　　要：嵌合抗原受体(CAR)-T细胞疗法改变了传统血液系统恶性肿瘤的治疗方法,显示出显著疗效。然而,CAR-T细胞因制作周期长、价格高昂和细胞因子释放综合征等副作用的限制,无法在临床广泛应用。自然杀伤(NK)细胞是机体固有免疫反应的重要组成部分,与CAR-T细胞相比,CAR-NK细胞的神经毒性、细胞因子释放综合征及引起移植物抗宿主病的概率均显著降低。临床前研究和临床试验证明了CAR-NK细胞疗法治疗恶性肿瘤的安全性和可行性,正逐渐成为肿瘤免疫治疗的研究热点,但也存在一些亟需解决的问题,仍需进一步优化构建策略以实现临床转化。本文综合国内外最新的研究成果,对CAR-NK细胞构建策略及其在肿瘤免疫治疗领域的研究进展作一综述,以期为NK细胞在恶性肿瘤治疗中的应用提供有价值的参考。Chimeric antigen receptor(CAR)-T cell therapy has changed the traditional treatment of hematological malignancies and has shown significant efficacy.However,the clinical application of CAR-T cells is limited by long production cycle,high price,and side effects such as cytokine storm,so it can not be widely used in clinical practice.Natural killer(NK)cells are an important part of the body's innate immune response.Compared with CAR-T cells,CAR-NK cells can significantly reduce the probability of neurotoxicity,cytokine storm,and graft versus host diseases.CAR-NK cell therapy is gradually becoming a research hotspot,but there are still some urgent problems to be solved,and further optimization of the construction strategy is needed to achieve its clinical translation.This paper will review the construction strategy and the research progress in tumor immunotherapy based on the latest literatures at home and abroad,in order to provide valuable reference for application of NK cells in the treatment of malignant tumors.

关 键 词：嵌合抗原受体 自然杀伤细胞 血液肿瘤 实体瘤 免疫治疗 

分 类 号：R457[医药卫生—治疗学] R979.1[医药卫生—临床医学]